Original Contribution |
From the University Department of Medicine, Manchester Royal Infirmary, Manchester, United Kingdom.
Correspondence to Michael I. Mackness, University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK.
AbstractHDL has been shown to prevent the oxidative modification of LDL. The antioxidant activity of HDL is believed to reside in its enzymes, particularly paraoxonase. Human serum paraoxonase (PON1) is closely associated with a specific HDL subfraction also containing apoA1 and clusterin. Recently PON1 has been implicated in the pathogenesis of atherosclerosis. We have examined the activity, concentration, and specific activity of PON1 in 50 patients on admission to hospital immediately after acute myocardial infarction (MI) and in 48 age- and gender-matched controls. Serum PON1 activity and concentration were significantly lower in patients with MI than in controls (activity, 221.5 [99.3 to 303.2] nmol · min-1 · mL-1 in controls and 130.1 [78.9 to 230.3] nmol · min-1 · mL-1 in MI patients [P<0.05]; concentration, 95.7 [73.2 to 135.5] µg/mL in controls and 35.4 [21.6 to 51.3] µg/mL in MI patients [P<0.001]). PON1-specific activity was significantly higher in patients with MI than in controls (1.5 [0.9 to 2.9] versus 3.4 [2.0 to 8.5] nmol · min-1 · µg-1 [P<0.001]) due to the much lower PON1 concentration. PON1 activity had risen significantly (P<0.05) to 158.1 (85.4 to 282.0) nmol · min-1 · mL-1 at day 42 but was still significantly less than that of controls. No significant variation in PON1 concentration occured in the days after MI or at 6 weeks. Also, no significant variation in specific activity was seen after MI. When the patients were divided into subgroups based on whether or not they received thrombolytic therapy on admission to hospital, no significant difference in PON1 levels was observed. Serum HDL cholesterol in patients with MI on admission was not significantly different than in controls, and the decrease that occurred by the fifth day after MI did not explain the lower PON1 levels. We conclude that low serum PON1 activity in patients with MI may be a consequence of the coronary event itself or could have been present before MI. The low PON1 activity was also not explicable on the basis of PON1 genotypes because the prevalence of genotypes associated with low activity was not sufficient to explain fully the difference in activity levels between patients and controls. The explanation for the low PON1 activity was most likely a decrease in serum PON1 concentration. The importance of PON1 as a predictive risk factor for MI should be assessed in future studies.
Key Words: paraoxonase myocardial infarction lipoproteins, HDL atherosclerosis
This article has been cited by other articles:
![]() |
Z.-G. She, W. Zheng, Y.-S. Wei, H.-Z. Chen, A.-B. Wang, H.-L. Li, G. Liu, R. Zhang, J.-J. Liu, W. B. Stallcup, et al. Human Paraoxonase Gene Cluster Transgenic Overexpression Represses Atherogenesis and Promotes Atherosclerotic Plaque Stability in ApoE-Null Mice Circ. Res., May 22, 2009; 104(10): 1160 - 1168. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Jamroz-Wisniewska, J Beltowski, Z Stelmasiak, and H Bartosik-Psujek Paraoxonase 1 activity in different types of multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 399 - 402. [Abstract] [PDF] |
||||
![]() |
F. F. Verit, A. Verit, H. Ciftci, O. Erel, and H. Celik Paraoxonase-1 Activity in Subfertile Men and Relationship to Sperm Parameters J Androl, March 1, 2009; 30(2): 183 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Richter, G. P. Jarvik, and C. E. Furlong Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate Substrates Circ Cardiovasc Genet, December 1, 2008; 1(2): 147 - 152. [Full Text] [PDF] |
||||
![]() |
J. W. C. Brock, A. J. Jenkins, T. J. Lyons, R. L. Klein, E. Yim, M. Lopes-Virella, R. E. Carter, (DCCT/EDIC) Research Group, S. R. Thorpe, and J. W. Baynes Increased methionine sulfoxide content of apoA-I in type 1 diabetes J. Lipid Res., April 1, 2008; 49(4): 847 - 855. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Connelly, G. F. Maguire, C. M. Picardo, J. F. Teiber, and D. Draganov Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma J. Lipid Res., January 1, 2008; 49(1): 245 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. F. Verit, O. Erel, and N. Celik Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease Hum. Reprod., January 1, 2008; 23(1): 100 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gaidukov and D. S. Tawfik The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity J. Lipid Res., July 1, 2007; 48(7): 1637 - 1646. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Browne, S. T. Koury, S. Marion, G. Wilding, P. Muti, and M. Trevisan Accuracy and Biological Variation of Human Serum Paraoxonase 1 Activity and Polymorphism (Q192R) by Kinetic Enzyme Assay Clin. Chem., February 1, 2007; 53(2): 310 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Carlson, P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease J. Lipid Res., May 1, 2006; 47(5): 1014 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dursun, E. Demirtas, A. Bayrak, and H. Yarali Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum. Reprod., January 1, 2006; 21(1): 104 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Voetsch, K. S. Benke, C. I. Panhuysen, B. P. Damasceno, and J. Loscalzo The Combined Effect of Paraoxonase Promoter and Coding Region Polymorphisms on the Risk of Arterial Ischemic Stroke Among Young Adults Arch Neurol, March 1, 2004; 61(3): 351 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Senti, M. Tomas, M. Fito, T. Weinbrenner, M.-I. Covas, J. Sala, R. Masia, and J. Marrugat Antioxidant Paraoxonase 1 Activity in the Metabolic Syndrome J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5422 - 5426. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Jarvik, T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1465 - 1471. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study Circulation, June 10, 2003; 107(22): 2775 - 2779. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Rozenberg, D. M. Shih, and M. Aviram Human Serum Paraoxonase 1 Decreases Macrophage Cholesterol Biosynthesis: Possible Role for Its Phospholipase-A2-Like Activity and Lysophosphatidylcholine Formation Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 461 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Jarvik, N. T. Tsai, L. A. McKinstry, R. Wani, V. H. Brophy, R. J. Richter, G. D. Schellenberg, P. J. Heagerty, T. S. Hatsukami, and C. E. Furlong Vitamin C and E Intake Is Associated With Increased Paraoxonase Activity Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1329 - 1333. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Voetsch, K. S. Benke, B. P. Damasceno, L. H. Siqueira, and J. Loscalzo Paraoxonase 192 Gln->Arg Polymorphism: An Independent Risk Factor for Nonfatal Arterial Ischemic Stroke Among Young Adults Stroke, June 1, 2002; 33(6): 1459 - 1464. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mackness, G. K. Davies, W. Turkie, E. Lee, D. H. Roberts, E. Hill, C. Roberts, P. N. Durrington, and M. I. Mackness Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1451 - 1457. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Durrington, B. Mackness, and M. I. Mackness Paraoxonase and Atherosclerosis Arterioscler Thromb Vasc Biol, April 1, 2001; 21(4): 473 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Navab, J. A. Berliner, G. Subbanagounder, S. Hama, A. J. Lusis, L. W. Castellani, S. Reddy, D. Shih, W. Shi, A. D. Watson, et al. HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids Arterioscler Thromb Vasc Biol, April 1, 2001; 21(4): 481 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Senti, M. Tomas, J. Marrugat, R. Elosua, and f. t. REGICOR Investigators Paraoxonase1-192 Polymorphism Modulates the Nonfatal Myocardial Infarction Risk Associated With Decreased HDLs Arterioscler Thromb Vasc Biol, March 1, 2001; 21(3): 415 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Jarvik, L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype Arterioscler Thromb Vasc Biol, November 1, 2000; 20(11): 2441 - 2447. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Navab, S. Y. Hama, G. M. Anantharamaiah, K. Hassan, G. P. Hough, A. D. Watson, S. T. Reddy, A. Sevanian, G. C. Fonarow, and A. M. Fogelman Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3 J. Lipid Res., September 1, 2000; 41(9): 1495 - 1508. [Abstract] [Full Text] |
||||
![]() |
C. C. Hedrick, K. Hassan, G. P. Hough, J. Yoo, S. Simzar, C. R. Quinto, S.-M. Kim, A. Dooley, S. Langi, S. Y. Hama, et al. Short-Term Feeding of Atherogenic Diet to Mice Results in Reduction of HDL and Paraoxonase That May Be Mediated by an Immune Mechanism Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1946 - 1952. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aviram, E. Hardak, J. Vaya, S. Mahmood, S. Milo, A. Hoffman, S. Billicke, D. Draganov, and M. Rosenblat Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions : PON1 Esterase and Peroxidase-Like Activities Circulation, May 30, 2000; 101(21): 2510 - 2517. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. James, I. Leviev, and A. Righetti Smoking Is Associated With Reduced Serum Paraoxonase Activity and Concentration in Patients With Coronary Artery Disease Circulation, May 16, 2000; 101(19): 2252 - 2257. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |